Bioluminescent imaging of ABCG2 efflux activity at the blood-placenta barrier

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Kumar, Jeyan S ^a   Wei, Bih Rong ^a   Madigan, James P ^a   Simpson, R Mark ^a   Hall, Matthew D ^a   Gottesman, Michael M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCG2 PROTEIN, MOUSE; ANTINEOPLASTIC AGENT; BENZOTHIAZOLE DERIVATIVE; BREAST CANCER RESISTANCE PROTEIN; D-LUCIFERIN; FIREFLY LUCIFERASE; GEFITINIB; LUMINESCENT AGENT; QUINAZOLINE DERIVATIVE;

ANIMAL; BLOOD BRAIN BARRIER; CELL CULTURE; CHORIOCARCINOMA; CYTOLOGY; DRUG EFFECTS; FEMALE; FLOW CYTOMETRY; IMAGE PROCESSING; LUMINESCENCE; MALE; METABOLISM; MOUSE; PATHOLOGY; PLACENTA; PREGNANCY; PROCEDURES; TISSUE DISTRIBUTION; TRANSGENIC MOUSE; TRANSPORT AT THE CELLULAR LEVEL; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY G, MEMBER 2; BENZOTHIAZOLES; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BLOTTING, WESTERN; CELLS, CULTURED; CHORIOCARCINOMA; FEMALE; FLOW CYTOMETRY; IMAGE PROCESSING, COMPUTER-ASSISTED; LUCIFERASES, FIREFLY; LUMINESCENT AGENTS; LUMINESCENT MEASUREMENTS; MALE; MICE; MICE, TRANSGENIC; PLACENTA; PREGNANCY; QUINAZOLINES; TISSUE DISTRIBUTION;

EID: 84957837677     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep20418     Document Type: Article

References (39)

1. Huppertz, B. The anatomy of the normal placenta. J Clin Pathol 61, 1296-1302, doi: 10.1136/jcp.2008.055277 (2008).
2. Prouillac, C. & Lecoeur, S. The role of the placenta in fetal exposure to xenobiotics: importance of membrane transporters and human models for transfer studies. Drug Metab Dispos 38, 1623-1635, doi: 10.1124/dmd.110.033571 (2010).
3. Behravan, J. & Piquette-Miller, M. Drug transport across the placenta, role of the ABC drug efflux transporters. Expert Opin Drug Metab Toxicol 3, 819-830, doi: 10.1517/17425255.3.6.819 (2007).
4. Evseenko, D., Paxton, J. W. & Keelan, J. A. Active transport across the human placenta: impact on drug efficacy and toxicity. Expert Opin Drug Metab Toxicol 2, 51-69, doi: 10.1517/17425255.2.1.51 (2006).
5. Mao, Q. BCRP/ABCG2 in the placenta: expression, function and regulation. Pharm Res 25, 1244-1255, doi: 10.1007/s11095-008-9537-z (2008).
6. Unadkat, J. D., Dahlin, A. & Vijay, S. Placental drug transporters. Curr Drug Metab 5, 125-131 (2004).
7. Gottesman, M. M., Ambudkar, S. V. & Xia, D. Structure of a multidrug transporter. Nat Biotechnol 27, 546-547, doi: 10.1038/nbt0609-546 (2009).
8. Raviv, Y., Pollard, H. B., Bruggemann, E. P., Pastan, I. & Gottesman, M. M. Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J Biol Chem 265, 3975-3980 (1990).
9. Gedeon, C., Behravan, J., Koren, G. & Piquette-Miller, M. Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta 27, 1096-1102, doi: 10.1016/j.placenta.2005.11.012 (2006).
10. Kraemer, J., Klein, J., Lubetsky, A. & Koren, G. Perfusion studies of glyburide transfer across the human placenta: implications for fetal safety. Am J Obstet Gynecol 195, 270-274, doi: 10.1016/j.ajog.2005.12.005 (2006).
11. Zhou, L. et al. The breast cancer resistance protein (Bcrp1/Abcg2) limits fetal distribution of glyburide in the pregnant mouse: an Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study. Mol Pharmacol 73, 949-959, doi: 10.1124/mol.107.041616 (2008).
12. Chung, F. S. et al. Positron emission tomography imaging of tissue P-glycoprotein activity during pregnancy in the non-human primate. Br J Pharmacol 159, 394-404, doi: 10.1111/j.1476-5381.2009.00538.x (2010).
13. Eyal, S. et al. Simultaneous PET imaging of P-glycoprotein inhibition in multiple tissues in the pregnant nonhuman primate. J Nucl Med 50, 798-806, doi: 10.2967/jnumed.108.059360 (2009).
14. Ke, A. B. et al. Modeling cyclosporine A inhibition of the distribution of a P-glycoprotein PET ligand, 11C-verapamil, into the maternal brain and fetal liver of the pregnant nonhuman primate: impact of tissue blood flow and site of inhibition. J Nucl Med 54, 437-446, doi: 10.2967/jnumed.112.111732 (2013).
15. Rudin, M. & Weissleder, R. Molecular imaging in drug discovery and development. Nat Rev Drug Discov 2, 123-131, doi: 10.1038/nrd1007 (2003).
16. Prescher, J. A. & Contag, C. H. Guided by the light: visualizing biomolecular processes in living animals with bioluminescence. Curr Opin Chem Biol 14, 80-89, doi: 10.1016/j.cbpa.2009.11.001 (2010).
17. Bakhsheshian, J. et al. Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2. Proc Natl Acad Sci USA 110, 20801-20806, doi: 10.1073/pnas.1312159110 (2013).
18. Bowie, L. J. Synthesis of firefly luciferin and structural analogs. Methods in Enzymology 57, 15-28 (1978).
19. Cao, Y. A. et al. Shifting foci of hematopoiesis during reconstitution from single stem cells. Proc Natl Acad Sci USA 101, 221-226, doi: 10.1073/pnas.2637010100 (2004).
20. Sheikh, A. Y. et al. Molecular imaging of bone marrow mononuclear cell homing and engraftment in ischemic myocardium. Stem Cells 25, 2677-2684, doi: 10.1634/stemcells.2007-0041 (2007).
21. Zoghbi, S. S. et al. 11C-loperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux. J Nucl Med 49, 649-656, doi: 10.2967/jnumed.107.047308 (2008).
22. Shepard, R. L., Cao, J., Starling, J. J. & Dantzig, A. H. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. Int J Cancer 103, 121-125, doi: 10.1002/ijc.10792 (2003).
23. Edinger, M. et al. Advancing animal models of neoplasia through min vivo bioluminescence imaging. Eur J Cancer 38, 2128-2136 (2002).
24. Greer, L. F., 3rd & Szalay, A. A. Imaging of light emission from the expression of luciferases in living cells and organisms: a review. Luminescence 17, 43-74, doi: 10.1002/bio.676 (2002).
25. Sato, A., Klaunberg, B. & Tolwani, R. In vivo bioluminescence imaging. Comp Med 54, 631-634 (2004).
26. Cao, J., Ying, X., Beyer, B. K. & DeLise, A. M. The use of optical imaging to assess the potential for embryo-fetal exposure to an exogenous material after intravaginal administration. Reprod Toxicol 48, 138-147, doi: 10.1016/j.reprotox.2014.05.010 (2014).
27. Bakhsheshian, J. et al. Overlapping substrate and inhibitor specificity of human and murine ABCG2. Drug Metab Dispos 41, 1805-1812, doi: 10.1124/dmd.113.053140 (2013).
28. Weidner, L. D. et al. The Inhibitor Ko143 Is Not Specific for ABCG2. J Pharmacol Exp Ther 354, 384-393, doi: 10.1124/jpet.115.225482 (2015).
29. Wang, H. et al. Expression of the breast cancer resistance protein (Bcrp1/Abcg2) in tissues from pregnant mice: effects of pregnancy and correlations with nuclear receptors. Am J Physiol Endocrinol Metab 291, E1295-1304, doi: 10.1152/ajpendo.00193.2006 (2006).
30. Yasuda, S., Itagaki, S., Hirano, T. & Iseki, K. Expression level of ABCG2 in the placenta decreases from the mid stage to the end of gestation. Biosci Biotechnol Biochem 69, 1871-1876 (2005).
31. Bloise, E. et al. Prenatal endotoxemia and placental drug transport in the mouse: placental size-specific effects. PLoS One 8, e65728, doi: 10.1371/journal.pone.0065728 (2013).
32. Hodyl, N. A., Stark, M. J., Butler, M. & Clifton, V. L. Placental P-glycoprotein is unaffected by timing of antenatal glucocorticoid therapy but reduced in SGA preterm infants. Placenta 34, 325-330, doi: 10.1016/j.placenta.2013.01.013 (2013).
33. Iqbal, M., Audette, M. C., Petropoulos, S., Gibb, W. & Matthews, S. G. Placental drug transporters and their role in fetal protection. Placenta 33, 137-142, doi: 10.1016/j.placenta.2012.01.008 (2012).
34. Yeboah, D. et al. Expression of breast cancer resistance protein (BCRP/ABCG2) in human placenta throughout gestation and at term before and after labor. Can J Physiol Pharmacol 84, 1251-1258, doi: 10.1139/y06-078 (2006).
35. Robey, R. W., Lin, B., Qiu, J., Chan, L. L. & Bates, S. E. Rapid detection of ABC transporter interaction: potential utility in pharmacology. J Pharmacol Toxicol Methods 63, 217-222, doi: 10.1016/j.vascn.2010.11.003 (2011).
36. Barsoum, J., Brown, R., McKee, M. & Boyce, F. M. Efficient transduction of mammalian cells by a recombinant baculovirus having the vesicular stomatitis virus G glycoprotein. Hum Gene Ther 8, 2011-2018, doi: 10.1089/hum.1997.8.17-2011 (1997).
37. Brimacombe, K. R. et al. A dual-fluorescence high-throughput cell line system for probing multidrug resistance. Assay Drug Dev Technol 7, 233-249, doi: 10.1089/adt.2008.165 (2009).
38. National Institutes of Health. Guide for the Care and Use of Laboratory Animals, 8th Ed., (The National Academies Press, 2001).
39. Sane, R., Agarwal, S., Mittapalli, R. K. & Elmquist, W. F. Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system. J Pharmacol Exp Ther 345, 111-124, doi: 10.1124/jpet.112.199786 (2013).